Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Cooper Companies operates two distinct medical device businesses: CooperVision (contact lenses, ~80% of revenue) and CooperSurgical (fertility/women's health devices, ~20%). CooperVision competes in the $9B global contact lens market with differentiated silicone hydrogel daily and specialty lenses (torics, multifocals), while CooperSurgical serves fertility clinics and OB/GYN practices with IVF consumables, surgical instruments, and genomic testing services.
CooperVision generates recurring revenue through consumable contact lenses sold via eye care professionals (ECPs) with 60%+ gross margins driven by proprietary manufacturing (PC Technology, Aquaform) and premium product mix shift toward daily disposables. CooperSurgical monetizes fertility treatment cycles through consumables (media, catheters at $200-500 per IVF cycle) and capital equipment placements that drive annuity-like consumable pull-through. Pricing power stems from clinical differentiation (Procrea media, MyoSmart myopia control), regulatory barriers (510k clearances, CE marks), and switching costs in ECP/clinic relationships. Operating leverage is moderate: manufacturing scale benefits offset by geographic expansion costs and R&D investments in new materials/modalities.
CooperVision constant currency revenue growth and daily disposable penetration rates (currently ~65% of CooperVision sales)
Gross margin trajectory driven by product mix shift toward premium silicone hydrogel dailies and specialty lenses (torics, multifocals)
CooperSurgical fertility market exposure and IVF cycle volumes globally (correlated with birth rate trends and reimbursement policies)
Geographic revenue mix, particularly Asia-Pacific growth rates and China market penetration
New product launches and regulatory approvals (MyoSmart myopia control lens expansion, new daily lens platforms)
M&A activity in fragmented fertility/women's health markets (historical strategy of tuck-in acquisitions)
Refractive surgery (LASIK, SMILE) and emerging vision correction technologies (orthokeratology, pharmaceutical myopia treatments) could reduce long-term contact lens market growth
Regulatory changes in reimbursement policies for fertility treatments (particularly in Europe where IVF coverage varies by country) or contact lens prescribing requirements
Demographic headwinds from declining birth rates in developed markets reducing fertility treatment addressable market
Online contact lens retailers (1-800 Contacts, Warby Parker) disintermediating traditional ECP channel and compressing pricing
Intense competition from larger players: Alcon (market leader, ~25% share), Johnson & Johnson Vision (Acuvue franchise), and Bausch + Lomb in contact lenses
CooperVision's #3 market position (~15% share) limits negotiating leverage with large retail chains and buying groups
Fertility market fragmentation with competition from Vitrolife (IVF media), Cook Medical (devices), and private equity-backed consolidators acquiring fertility clinic networks
Patent expirations on key lens materials and manufacturing processes enabling generic/private label competition
Debt/Equity of 0.34x is modest, but $2.8B gross debt requires $400M+ annual free cash flow for deleveraging and dividend sustainability
Acquisition-driven growth strategy creates integration risk and potential for overpaying in competitive M&A processes (CooperSurgical built through 30+ acquisitions)
Foreign exchange exposure with ~60% revenue outside U.S. and manufacturing concentrated in Puerto Rico, UK, Costa Rica creates translation and transaction risk
low-to-moderate - Contact lenses are medical necessities with high patient retention (90%+ annual repurchase rates), providing recession-resistant revenue. However, discretionary elements exist: new patient fittings decline in recessions, patients may downgrade from dailies to monthlies, and elective fertility treatments are highly discretionary ($15K-25K per IVF cycle). CooperVision's 80% revenue weight provides defensive characteristics, but CooperSurgical fertility business is procyclical and sensitive to consumer confidence and discretionary healthcare spending.
Rising rates have modest negative impact through two channels: (1) higher cost of debt on $2.8B gross debt (though 34% Debt/Equity is manageable), and (2) compressed valuation multiples for medical device growth stocks as discount rates rise. Operationally, higher rates may reduce fertility treatment demand as patients finance IVF cycles through savings or credit. However, core contact lens business is largely rate-insensitive given consumable nature and insurance/FSA reimbursement coverage.
Minimal direct credit exposure. Revenue is B2B (selling to ECPs, distributors, fertility clinics) with limited consumer financing. Receivables risk is low given fragmented customer base and 60-90 day payment terms. Balance sheet has $2.8B debt but strong interest coverage (16.7% operating margin supports 5x+ EBIT/Interest). Credit conditions affect M&A capacity and acquisition financing costs, which is relevant given historical growth-through-acquisition strategy in CooperSurgical.
growth-at-a-reasonable-price (GARP) - Attracts investors seeking durable mid-single-digit organic growth with margin expansion potential, trading at 18.8x EV/EBITDA (premium to diversified med-tech at 15-16x but below pure-play ophthalmology at 20x+). Defensive healthcare exposure with 60%+ gross margins and recurring revenue appeals to quality-focused funds. Limited dividend yield (not a dividend stock) but consistent FCF generation supports buybacks and M&A optionality.
moderate - Medical device stocks exhibit lower volatility than broader market (beta typically 0.8-1.0) given recurring revenue and non-discretionary demand. However, CooperSurgical's fertility exposure adds cyclicality, and FX volatility from international operations creates quarterly earnings variability. Stock has demonstrated 15-20% drawdowns during broader market corrections but recovers faster than cyclical healthcare (hospitals, elective procedures).
